Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

Share Price is delayed by 15 minutes
Get Live Data
1.10    0.00 (0.00%)
Bid:
1.00
Ask:
1.10
Spread: 0.10 (10.00%)
Market Cap: £25.80m
PXS Live PriceLast checked at - London Stock Exchange

Intraday Provexis Share Chart

AGM Statement

24 Aug 2011 07:00

RNS Number : 9007M
Provexis PLC
24 August 2011
 



24 August 2011

Provexis plc

 

AGM Statement

 

Provexis plc ("Provexis" or the "Company"), the life-science business that develops, licenses and markets scientifically-proven functional food, sports nutrition and medical food technologies, will hold its Annual General Meeting in Reading later today.

 

At the meeting Dawson Buck, the non-executive Chairman of the Company, will give the following update on developments:

 

 "The Company has made major progress over the past 18 months, specifically with the commercialisation of its lead technology Fruitflow and the recent acquisition of Science in Sport ("SiS").

 

Following the announcement of the long-term Alliance with DSM Nutritional Products ("DSM") in June 2010, DSM has made good progress in marketing Fruitflow to a broad range of global markets, attracting positive interest from a wide range of global, multinational and national brand owners in the functional food and dietary supplement sectors. The Alliance expects to see initial revenues from Fruitflow commence in the coming months and the Company looks forward to updating shareholders on this matter as and when appropriate.

 

The Company acquired SiS in June 2011. The Board are very pleased with the business and the opportunities it presents to the enlarged group. The Board strongly believe that through targeted investment SiS will achieve significant like for like revenue growth and margin improvement. As part of this investment the Directors expect to transfer production and distribution to a larger facility later in the year, in line with growth plans for the business. Defined marketing and selling strategies, together with new product launches and efficiencies from the supply chain, will underpin sales and profit growth in the business during 2012.

 

The SiS business presents the Company with a number of opportunities to bring new products to market to support 2012 growth; consequently the Board is currently reviewing the overall project pipeline for the Company in order to allocate resource and capital in the most effective way, in line with our growth targets.

 

We have a busy year ahead of us, with the main focus of the executive team being on delivering revenues from Fruitflow and growing the sales and profitability of the SiS business. We have sufficient resources to hand to deliver our targets and I look forward to a year of strong progress."

 

-ends-

 

For further information please contact:

 

Stephen Moon, Chief Executive

Provexis plc Tel: 01753 833177

 

Bobbie Hilliam Tel: 020 7071 4317

Evolution Securities

 

Haggie Financial LLP: Tel: 020 7417 8989

Matthew Longbottom/Peter Rigby matthew.longbottom@haggie.co.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMEXLFLFVFLBBB
Date   Source Headline
31st Jul 20127:00 amRNSFinal Results
27th Jul 20127:00 amRNSNotice of Results
31st May 20127:00 amRNSTotal Voting Rights
17th May 20127:00 amRNSDraw Down of Funds and Issue of Equity
24th Apr 20127:00 amRNSScience in Sport brand relaunch
23rd Apr 20124:31 pmRNSAdditional Listing
2nd Apr 20127:00 amRNSDirectorate Change
30th Mar 201211:46 amRNSTotal Voting Rights Update
30th Mar 20127:00 amRNSPre-Close Update
16th Mar 20124:35 pmRNSPrice Monitoring Extension
12th Mar 20124:40 pmRNSSecond Price Monitoring Extn
12th Mar 20124:35 pmRNSPrice Monitoring Extension
12th Mar 20127:00 amRNSScience in Sport Update
14th Feb 20127:00 amRNSFruitflow update
9th Jan 20124:40 pmRNSSecond Price Monitoring Extn
9th Jan 20124:35 pmRNSPrice Monitoring Extension
9th Jan 20127:00 amRNSProvexis to fuel GB rowing team
7th Dec 20113:01 pmRNSAdditional Listing
1st Dec 20117:00 amRNSChange of adviser
1st Dec 20117:00 amRNSInterim Results
28th Nov 20117:00 amRNSNotice of Interim Results
8th Nov 20117:00 amRNSRenewal of £25 million Equity Financing Facility
24th Aug 20113:24 pmRNSResult of AGM
24th Aug 20117:00 amRNSAGM Statement
8th Aug 20114:40 pmRNSSecond Price Monitoring Extn
8th Aug 20114:35 pmRNSPrice Monitoring Extension
4th Aug 20114:40 pmRNSSecond Price Monitoring Extn
4th Aug 20114:35 pmRNSPrice Monitoring Extension
1st Aug 20115:22 pmRNSNotice of AGM
29th Jul 20117:00 amRNSTotal Voting Rights
26th Jul 20114:46 pmRNSResult of open offer
15th Jul 20114:35 pmRNSHolding(s) in Company
14th Jul 201110:44 amRNSHolding(s) in Company
12th Jul 20114:23 pmRNSHolding(s) in Company
12th Jul 20119:17 amRNSHolding(s) in Company
11th Jul 20111:42 pmRNSChange of Registered Office
5th Jul 20117:00 amRNSOpen Offer
30th Jun 20114:55 pmRNSHolding(s) in Company
30th Jun 20117:00 amRNSTotal Voting Rights
28th Jun 20113:34 pmRNSHolding(s) in Company
24th Jun 201112:08 pmRNSCompletion of the acquisition of SiS
20th Jun 20119:36 amRNSDirector Dealing
17th Jun 20114:15 pmRNSGrant of Options
17th Jun 20117:00 amRNSFinal Results
17th Jun 20117:00 amRNSAcquisition of Science in Sport Ltd
1st Jun 20117:00 amRNSUpdate on Crohn's disease trial
1st Jun 20117:00 amRNSAppointment of New Product Director
1st Jun 20117:00 amRNSSigning of Development Agreement
31st Mar 20117:00 amRNSPre-close update
28th Feb 20118:49 amRNSDevelopment Agreement - Replacement announcement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.